Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 4/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.46 |
| ▸ | PDE4A | P27815 | 2/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | EED | O75530 | 1/20 | 0.41 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.41 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.41 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.41 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21612813 | 0.91 | PDE4D (0.49) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL21612772 | 0.85 | PDE4B (0.44) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL30590963 | 0.81 | PDE4B (0.46) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL31352847 | 0.81 | PDE4B (0.46) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL28983485 | 0.80 | GPR119 (0.50) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL21612833 | 0.77 | PDE4D (0.47) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL1446669 | 0.77 | KDM1A (0.48) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL3904222 | 0.76 | PDE4D (0.50) | PDE4BPDE4DPDE4APDE4CGPR119 | |
| SCHEMBL21616272 | 0.76 | KDM4E (0.43) | PDE4BPDE4DPDE4APDE4CKDM4E | |
| SCHEMBL3160194 | 0.76 | GPR119 (0.52) | PDE4BPDE4DPDE4APDE4CGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-3822263-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2021-05-19 | — | — | EP | disclosed |
| CN-112334460-A | Biaryl ether type quinazoline derivative | 第一三共株式会社 | 2021-02-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | ERBB2, EGFR, ERBB3 | PDE4B 3483/4885PDE4D 3905/4885PDE4A 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.